DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) ...
Hosted on MSN
Baxter targets 5%-6% 2025 revenue growth amid Novum IQ pump success and operational recovery
Earnings Call Insights: Baxter International Inc. (NYSE:BAX) Q4 2024 Interim CEO Brent Shafer highlighted the completion of the Vantive sale as a significant milestone in Baxter's transformation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback